Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Nutr.

Sec. Clinical Nutrition

Volume 12 - 2025 | doi: 10.3389/fnut.2025.1642166

Vitamin D and Cancer-Related Fatigue in Elderly Patients: Mechanisms and Therapeutic Insights—A Narrative Review

Provisionally accepted
Yu  ZhangYu Zhang1*Juan  WuJuan Wu2Jinzheng  ChiJinzheng Chi3
  • 1Zhejiang Kangjing Hospital, Hangzhou, China
  • 2The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
  • 3Pei County People's Hospital, Xuzhou, China

The final, formatted version of the article will be published soon.

Cancer-related fatigue (CRF) is a prevalent and debilitating symptom in elderly cancer patients. According to the National Comprehensive Cancer Network (NCCN) and international consensus, CRF is defined as a persistent, multidimensional fatigue disproportionate to activity, unrelieved by rest, and involving physical, emotional, and cognitive domains. Diagnosis requires standardized patient-reported scales, objective biomarkers (e.g., inflammatory and metabolic indices), and exclusion of comorbidities such as anemia or organ dysfunction. In elderly patients, CRF arises from interrelated alterations, including chronic inflammation, neuroendocrine dysregulation, circadian disruption, and progressive muscle atrophy, that perpetuate a vicious cycle. Current treatments encompass pharmacological agents (e.g., corticosteroids, psychostimulants, antidepressants, and traditional Chinese medicine, primarily studied in China) and non-pharmacological modalities (e.g., exercise, acupuncture, and cognitive-behavioral therapy), yet efficacy remains inconsistent. Emerging approaches such as mitochondrial modulators and bright light therapy are expanding the therapeutic landscape. Vitamin D, particularly cholecalciferol (vitamin D3), is commonly deficient in older adults and shows promise in alleviating CRF through anti-inflammatory, immunomodulatory, neuroprotective, and myogenic effects. This narrative review summarizes current evidence on vitamin D3's mechanisms and clinical value, highlights its role as a multi-target modulator, and explores its integration into personalized CRF management. Future studies should refine dosing strategies, clarify responses in the elderly, and assess the synergy between conventional and novel interventions.

Keywords: Cancer-related fatigue, Elderly cancer patients, Vitamin D, Inflammation, muscle atrophy, personalized therapy

Received: 11 Jun 2025; Accepted: 12 Sep 2025.

Copyright: © 2025 Zhang, Wu and Chi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yu Zhang, 19523012805@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.